Voriconazole treatment for less-common, emerging, or refractory fungal infections

Clinical Infectious Diseases

Volumn 36, Issue 9, 2003, Pages 1122-1131

  Perfect, John R ^a,l   Marr, Kieren A ^b   Walsh, Thomas J ^c   Greenberg, Richard N ^d   DuPont, Bertrand ^g   De La Torre Cisneros, Juliàn ^h   Just Nübling, Gudrun ⁱ   Schlamm, Haran T ^e   Lutsar, Irja ^j   Espinel Ingroff, Ana ^f   Johnson, Elizabeth ^k  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e PFIZER INC   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

ⁱ GOETHE UNIVERSITY   (Germany)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^k Public Health Laboratory   (United Kingdom)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FUSARIUM; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; NEPHROTOXICITY; PHOTOPHOBIA; PRIORITY JOURNAL; SCEDOSPORIUM; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; HUMANS; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 0038556830     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374557     Document Type: Article

References (42)

1. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
2. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1:176-82.
3. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8.
4. Hegener P, Troke PF, Fatkenheuer G. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12:2227-8.
5. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
6. Walsh T, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
7. Herbrecht R, Neuville S, Letscher-Bru V, Natarajan-Ame S, Lortholary O. Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment. Drugs Aging 2000; 17:339-51.
8. Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-14.
9. Schoniger S, Hildebrand A, Richer A. Invasive pulmonary aspergillosis refractory to amphotericin B in a patient with persisting neutropenia: successful treatment with voriconazole [abstract P744]. In: Programs and abstracts of the 9th European Congress of Clinical Microbiology and Infectious Diseases (Berlin). 1999.
10. Machetti M, Zotti M, Veroni L. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2:140-4.
11. Hoepelman AM, Hodges MR, Lutsar I. Cerebral aspergillosis and scedosporiosis: a new treatment option for children with life threatening cerebral fungal infection [abstract]. In: Programs and abstracts of the 18th European Society for Pediatric Infectious Diseases (Noordwijk, The Netherlands). 2000.
12. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997;97:663-5.
13. de Sevaux RG, Kullberg BJ, Verweij PE. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. Clin Infect Dis 1998; 26:996-7.
14. van't Hek LGFM, Verweij PE, Weemaes CRM. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157:1694-6.
15. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932-3.
16. Munoz P, Marin M, Tornero P. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499-501.
17. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection [abstract 305]. In: Programs and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Alexandria, VA: Infectious Diseases Society of America, 2000.
18. Nesky MA, McDougal EC, Peacock JE Jr. Pseudoallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudoallescheriasis. Clin Infect Dis 2000; 31:673-6.
19. Girmenia C, Luzi G, Nomaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermium infection: case report. J Clin Microbiol 1998; 36:1436-8.
20. Hilmarsdottir J, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis 2000; 32:331-2.
21. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150:101-15.
22. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954-8.
23. Espinel-Ingroff A. In vitro activities of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36:198-202.
24. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution susceptibility testing of yeasts. Approved standard M27-A. Wayne, PA: NCCLS, 1997.
25. Espinel-Ingroff A, Bartlett M, Bowden RA, et al. Multicenter evaluation of proposed procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35:139-43.
26. Collett D. Modeling survival data in medical research. New York: Chapman & Hall, 1994.
27. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
28. Maertens J, Road I, Sable CA. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B and amphotericin B lipid formulations [abstract 371]. In: Programs and abstracts of the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2000.
29. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12:1147-201.
30. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case fatality rate: systemic review of the literature. Clin Infect Dis 2001; 32:358-66.
31. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000; 79:250-60.
32. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33:1824-33.
33. Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenia patient. Oncology 2001; 15:351-63.
34. Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid organ transplant recipients with invasive fungal infections. Clin Transplant 2000; 14:329-39.
35. Kaplan JE, Jones JL, Dykewicz CA. Protists as opportunistic pathogens: public health impact in the 1990s and beyond. J Eukaryot Microbiol 2000; 47:15-20.
36. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
37. Krcmery V, Spanik S, Kunova A, Trupl J. Breakthrough fungemia appearing during empiric therapy with amphotericin B. Chemotherapy 1997; 43:367-70.
38. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1:229-36.
39. Marr KA, Carter RA, Crippa RA, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
40. Verweij PE, Brinkman K, Kremer HPH, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37:1186-9.
41. Potoski BA, Brown J. Safety of voriconazole. Clin Infect Dis 2002; 35:1273-5.
42. Tan KKC, Brayshaw N, Oaks M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials [abstract A-18]. In: Programs and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.